Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with HR-positive, HER2-negative stages II and III breast cancer at high-risk for recurrence following surgery. FDA also approved ribociclib and…
English